Mise à jour sur les lignes directrices du traitement du VIH

Español (soon!) - November 20, 2008

CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.

Conference

"Mise à jour sur les lignes directrices du traitement du VIH"
Dr. Richard Lalonde (biography)
French - 2003-11-30 - 73 minutes

(31 slides)

(50 slides)

Summary :
Les thérapies antirétrovirales, si elles ne permettent toujours pas de guérir l'infection par le VIH, ont transformé l'évolution de la maladie, devenue chronique, et fait chuté drastiquement les taux de mortalité reliée au VIH. Le Dr Richard Lalonde aborde, dans une perspective historique, les particularités des thérapies antirétrovirales actuelles et à venir : leurs bénéfices, leurs complications, leurs indications. Les nouvelles générations de médicaments antirétroviraux visent une plus grande efficacité, une moindre toxicité et une plus grande facilité d'administration.

Copyright © 2004 E-MedHosting.com Inc.

Learning objectives :
En visionnant cette présentation, l'apprenant prendra connaissance :
- des bénéfices de la trithérapie antirétrovirale
- ses complications : lipodystrophie, dyslipidémies, résistance
- ses indications : quand la débuter, avec quels médicamanets ? selon les lignes directrices du DHHS et du Québec

Bibliographic references :
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60.

van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003 Oct 17;17(15):2227-36.

Monforte, Antonella d'Arminio; Lepri, Alessandro Cozzi; Rezza, Giovanni; Pezzotti, Patrizio; Antinori, Andrea; Phillips, Andrew N.; Angarano, Gioacchino; Colangeli, Vincenzo; Luca, Andrea De; Ippolito, Giuseppe; Caggese, Liliana; Soscia, Fabrizio; Filice, Gaetano; Gritti, Francesco; Narciso, Pasquale; Tirelli, Umberto; Moroni, Mauro; for the I.CO.N.A. Study Group Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 14(5):499-507, March 31, 2000.

Dieleman, Jeanne P.; Jambroes, Marielle; Gyssens, Inge C.; Sturkenboom, Miriam C. J. M.; Stricker, Bruno H. Ch.; Mulder, Wilhelmina M. C.; de Wolf, Frank; Weverling, Gerrit-Jan; Lange, Joep M. A.; Reiss, Peter; Brinkman, Kees; on behalf of the ATHENA Study Group Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort. AIDS. 16(5):737-745, March 29, 2002.

Mallon, Patrick WG; Miller, John; Cooper, David A; Carr, Andrew Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 17(7):971-979, May 2, 2003.

Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med. 1998 Oct 29;339(18):1296.

The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group Combination Antiretroviral Therapy and the Risk of Myocardial Infarction N Engl J Med 2003; 349:1993-2003, Nov 20, 2003.

Kent DM, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis. 2003 Jul 1;37(Suppl 1):S13-24.

Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21-30.

Bartlett, John A.; DeMasi, Ralph; Quinn, Joseph; Moxham, Cary; Rousseau, Franck Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 15(11):1369-1377, July 27, 2001.

Jonathan E. Kaplan, Debra L. Hanson, David L. Cohn, John Karon, Susan Buskin, Melanie Thompson, Patricia Fleming, Mark S. Dworkin, and the Adult and Adolescent Spectrum of HIV Disease Project Investigators When to Begin Highly Active Antiretroviral Therapy? Evidence Supporting Initiationof Therapy at CD4+ Lymphocyte Counts <350 cells/L Clinical Infectious Diseases 2003;37:951-958

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003 Apr 15;138(8):620-6.

Login

	Please log in and get access to thousands of resources about HIV disease and its treatment.
	Already a member?
	Username :
	Password :

	Lost your password?

Search our database

Find the information that you are looking for in over +3000 resources.

ezCME: HIV - Insulin Resistance - C-Reactive Protein (CRP) - ADHD - Sleep Disorder - Prostate Health - Hemophilia - Transplantation

CMEonHIV is owned by E-MedHosting.com.

Copyright @ 2002-2008 E-MedHosting.com. All rights reserved. Disclaimer | Sponsor Disclaimer
Powered by Multiwebcast - webcast services

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR
BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.